Form 4: KALA BIO, Inc. Executive Todd Bazemore Reports Stock Option Grant

Todd Bazemore, Interim CEO, President, and COO of KALA BIO, Inc., reports the grant of a stock option for 45,200 shares.

Summary

• On March 7, 2025, Todd Bazemore, Interim Chief Executive Officer, President, and Chief Operating Officer of KALA BIO, Inc., was granted a stock option to purchase 45,200 shares of common stock at an exercise price of $7.05.
• The options vest in monthly installments over one year, starting February 11, 2025, contingent upon continued employment with the Issuer.
• The options expire on March 6, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The vesting schedule is a positive sign, but the overall impact is likely to be moderate.

Positives

• The granting of stock options to the Interim CEO, President, and COO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued employment and performance over the next year.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive team.
• Employees may see this as a sign of confidence in the company's future.

Key Dates